| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | FUNCTIONAL FLUIDICS INC. | 440 BURROUGHS STREET SUITE 641 | DETROIT | MI | 48202-3474 | WAYNE | USA | R43HL172384 | Development of POC system for patient condition and treatment monitoring in Sickle Cell Disease through hypoxia-induced sickling | 000 | 1 | NIH | 10/17/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $106,682 ) |
| | 2024 | 2024 | FUNCTIONAL FLUIDICS INC. | 440 BURROUGHS STREET SUITE 641 | DETROIT | MI | 48202-3474 | WAYNE | USA | R43HL172384 | Development of POC system for patient condition and treatment monitoring in Sickle Cell Disease through hypoxia-induced sickling | 000 | 1 | NIH | 9/17/2024 | $265,347 |
| | 2024 | 2020 | FUNCTIONAL FLUIDICS INC. | 440 BURROUGHS STREET SUITE 641 | DETROIT | MI | 48202-3474 | WAYNE | USA | R43FD006939 | Validation of Erythrocyte Mechanical Fragility as a biometric for performance assessment of Circulatory Support Devices | 000 | 1 | FDA | 4/27/2024 | -$158,665 |
|
| Issue Date FY: 2023 ( Subtotal = -$200 ) |
| | 2023 | 2020 | FUNCTIONAL FLUIDICS INC. | 440 BURROUGHS STREET SUITE 641 | DETROIT | MI | 48202-3474 | WAYNE | USA | R43FD006939 | Validation of Erythrocyte Mechanical Fragility as a biometric for performance assessment of Circulatory Support Devices | 000 | 1 | FDA | 12/16/2022 | $0 |
| | 2023 | 2020 | FUNCTIONAL FLUIDICS INC. | 440 BURROUGHS STREET SUITE 641 | DETROIT | MI | 48202-3474 | WAYNE | USA | R43FD006939 | Validation of Erythrocyte Mechanical Fragility as a biometric for performance assessment of Circulatory Support Devices | 001 | 1 | FDA | 6/2/2023 | $0 |
| | 2023 | 2019 | FUNCTIONAL FLUIDICS INC. | 440 BURROUGHS STREET SUITE 641 | DETROIT | MI | 48202-3474 | WAYNE | USA | R43HL145898 | Co-Development of a Novel Anti-Sickling Therapy and Its Companion Diagnostic for Future Sickle Cell Disease Management | 000 | 1 | NIH | 2/2/2023 | -$200 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2020 | FUNCTIONAL FLUIDICS INC. | 440 BURROUGHS ST STE 641 | DETROIT | MI | 48202-3474 | WAYNE | USA | R43FD006939 | Validation of Erythrocyte Mechanical Fragility as a biometric for performance assessment of Circulatory Support Devices | 000 | 1 | FDA | 1/27/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | FUNCTIONAL FLUIDICS INC. | 440 BURROUGHS ST STE 641 | DETROIT | MI | 48202-3474 | WAYNE | USA | OT2HL152642 | Cell adhesion and red blood cell mechanical fragility as promising biomarker/endpoint for developing curative therapies in sickle cell disease | 000 | 1 | NIH | 4/23/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $168,087 ) |
| | 2020 | 2020 | FUNCTIONAL FLUIDICS LLC | 708 BALFOUR ST | GROSSE POINTE PARK | MI | 48230-1812 | WAYNE | USA | R43FD006939 | Validation of Erythrocyte Mechanical Fragility as a biometric for performance assessment of Circulatory Support Devices | 000 | 1 | FDA | 8/18/2020 | $168,087 |
| | 2020 | 2019 | FUNCTIONAL FLUIDICS LLC | 708 BALFOUR ST | GROSSE POINTE PARK | MI | 48230-1812 | WAYNE | USA | R43HL145898 | Co-Development of a Novel Anti-Sickling Therapy and Its Companion Diagnostic for Future Sickle Cell Disease Management | 000 | 1 | NIH | 7/15/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $224,512 ) |
| | 2019 | 2019 | FUNCTIONAL FLUIDICS LLC | 708 BALFOUR ST | GROSSE POINTE PARK | MI | 48230-1812 | WAYNE | USA | R43HL145898 | Co-Development of a Novel Anti-Sickling Therapy and Its Companion Diagnostic for Future Sickle Cell Disease Management | 000 | 1 | NIH | 2/22/2019 | $224,512 |
| | 2019 | 2019 | FUNCTIONAL FLUIDICS LLC | 708 BALFOUR ST | GROSSE POINTE PARK | MI | 48230-1812 | WAYNE | USA | R43HL145898 | Co-Development of a Novel Anti-Sickling Therapy and Its Companion Diagnostic for Future Sickle Cell Disease Management | 001 | 1 | NIH | 4/5/2019 | $0 |
|
|
